Palmoplantar pustulosis

2 trials 2 recruiting MedDRA PT
2 Registered trials
2 Recruiting
2 Unique sponsors
2 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 1
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
JAK inhibitor 1 substance
Monoclonal antibody (humanized) 1 substance
Phase III: 1 Phase II: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase III

1 trial
  • UCB Biopharma Commercial
    BIMEKIZUMAB
    2024-520337-80-00 8 countries 2026 n=190
    Recruiting

Phase II

1 trial
  • Leo Pharma A/S Commercial
    DELGOCITINIB
    2024-518856-21-00 2 countries 2025 n=70
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Leo Pharma A/S Commercial 1 Phase II 1
UCB Biopharma Commercial 1 Phase III 1
New trials by year
2025
1
2026
1
← All indication landscapes